Presented by expert speakers, our webinars will give you advance insight into topics that will be covered at the event.
Can’t make the date? Still register to receive the webinar recording afterwards.
The Design And Development Of A Connected Inhalation System To Help With Monitoring And Patient Adherence
Wednesday, 15 January 2020 | 8:30am PST / 11:30am EST / 4:30pm GMT
- Understanding the unmet needs for clinical trials and commercial use of a connected inhalation system
- Selecting design and development partners for a connected ecosystem
- Describing the critical clinical and patient workflows that drive adoption
- Ensuring you have an engaging and motivating user experience
Our complimentary webinar is for respiratory and inhalation experts interested in learning more about the latest innovations in digital health. This is a free event open to all, so why not register and benefit from the expertise of our speakers?
Paul is the Head of Smart Devices at Roche / Genentech. Paul has 20 years of experience in medical device R&D, strategic marketing, product management, clinical research, and medical informatics.
Prior to Roche / Genentech, Paul was with Becton Dickinson(BD), as Worldwide Director of Strategic Marketing in their Pharmaceutical Systems business. Paul and his team were responsible for all upstream and downstream marketing strategy for BD’s self-injection business, including pen injectors, autoinjectors, and wearable patch injectors.
Prior to that role, Paul was with WellDoc, Inc. as Director of Product Marketing, where he built and led the marketing team and was responsible for product management activities for WellDoc’s portfolio of mobile health solutions. He was also the Core Team Leader for WellDoc’s landmark BlueStar™ product, a class II medical device and the world’s first reimbursed, prescription-only software for type 2 diabetes.
Paul’s prior experience includes 10 years at BD in the Diabetes Care business. Paul was responsible for the development and launch of the award-winning BD InterActiv® Diabetes Software, and was a member of the joint BD / Medtronic core team that launched ParadigmLink®, the world’s first wireless blood glucose meter.
Paul holds four issued patents in medical software and drug delivery devices and multiple patent applications covering software and medical devices. He is also an author and co-author of numerous peer-reviewed articles in medical informatics and in diabetes. His education background includes undergraduate studies in cognitive science and graduate work in health informatics and finance at the University of Minnesota and New York University.
Understanding Supersaturation Of Small Molecule To Improve Oral Bioavailability
Wednesday, 5 February 2020 | 6:30am PST / 9:30am EST / 2:30pm GMT
Hosted by Sudhakar Garad, Global Head of Chemical and Pharmaceutical Profiling, Novartis Institutes for BioMedical Research
The majority of new chemical entities being discovered in many disease areas have a poor aqueous and bio relevant solubility. The phase behavior of supersaturated solutions in vivo of relatively hydrophobic drugs, were studied in the absence / presence of polymeric excipients. An induction time for crystallization in the presence/absence of polymeric additives is very important to maintain the supersaturation and its impact on absorption/bioavailability. In general when insoluble molecule added to aqueous media (bio relevant) at concentrations above the amorphous solubility, a phase separation (turbidity, precipitation) were observed prior to crystallization, resulting in a short-lived, drug-rich monocrystalline phase or an amorphous phase. The addition of polymers was found to greatly extend the lifetime of the supersaturated system, delaying the onset of precipitation or crystallization from a few minutes to a few hours. Therefore, the addition of polymers prevents from precipitating the insoluble molecule once a threshold concentration was exceeded, they did inhibit precipitation /crystallization, leading to a solution with prolonged supersaturation. Most commonly used cellulosic polymers to maintain supersaturation are polyvinylpyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC), and hydroxypropylmethyl cellulose acetate succinate (HPMCAS). In this presentation will understand the process, assay and rational in selection of polymer based on physicochemical properties of insoluble molecule.
Our free webinar is for professionals involved in Formulation and drug delivery interested in hearing about innovative drug solubility. This is a free event open to all, so why not register and benefit from the expertise of our speakers?
Sudhakar Garad received his Ph.D. from the Bombay College of Pharmacy, University of Mumbai, India in 1998 in Pharmaceutical Drug Delivery Technology with Dr, M.S Nagarsenker. Soon after completion of his Ph.D., he worked with Pfizer, India for less than a year in clinical research. Taking into consideration his excellent credentials during his Ph.D, he was selected as a post-doctoral fellow at the University of Connecticut to understand micro-environmental properties above dissolving surface of the polymers. After his post-doctoral fellowship, he worked with Vertex pharmaceutical for a period of three years as Senior Investigator in formulation development group. After Vertex, he joined Novartis as a Group Head. He worked with Novartis for 9 years and joined as a Director of formulation development at Cubist Pharmaceuticals/Merck for 2.5 years. Currently Sudhakar is working as a Global head of Chemical and Pharmaceutical profiling (Discovery Pharmaceutics) and Disease Area Head (New Indications) at Novartis. His primary role is collaborate with research colleagues and build the right biopharmaceutical properties into new chemical entities, if not enable them via solubility/dissolution enhancement technologies to expedite molecules into tox and clinical studies. He is also responsible for enabling research, clinical and commercial molecules via novel delivery technologies (Brain targeting, permeability enhancement, TI improvement etc). He has many publications, book chapters and patents. In last 20 years of his career he has taken more than 200 new chemical entities in clinical studies across dozen disease areas ( CVM, Oncology, ATI, MS, Respiratory, NS, GI, Antibacterial, Tropical diseases, HCV etc), via oral, parenteral, inhalation and transdermal route of administration. He serves as a technical R and D expert to research Disease Area for hematology, hepatology and kidney disease area.
Ocular Biopharmaceutics: Impact of Modeling and Simulation on Topical Ophthalmic Formulation Development
Wednesday, 12 February 2020 | 8:00am PST / 11:00am EST / 4:00pm GMT
Hosted by Hovik Gukasyan, Associate Director, Early Development Formulation & Physical Chemistry, Allergen
The estimation of ocular pharmacokinetics (PK) in various eye tissues is limited because of sampling challenges. Computational modeling and simulation (M&S) tools underpinning the elucidation of drug access routes and prediction of ocular exposure are essential for the mechanistic assessment of biopharmaceutics in the eye. Therefore, theoretical and experimental evaluation of ocular absorption and transit models is necessary. Biopharmaceutical parameter sensitivity analysis based on permeability and drug dose illustrates utility in ocular drug delivery assessment, which could have innovative and cost-saving impacts on ophthalmic product development and therapeutic bioequivalence (BE) evaluations
Our free webinar is for professionals involved in Formulation and drug delivery interested in hearing about ocular drug delivery. This is a free event open to all, so why not register and benefit from the expertise of our speakers?
In 1999 Hovik received a BS in Chemistry from the University of Southern California (USC) with an academic minor in Biological Sciences. In 2003 He received a PhD in Pharmaceutical Sciences from USC School of Pharmacy under the supervision of Prof. Vincent H.L. Lee. With a thesis on ocular physiology and transport oxidative inflammatory eye disease. 39 peer-reviewed papers, including 2 book chapters, 2 guest-edited topical thematic collections and 87 abstract presentations as posters or invited talks. Hovik has one patent/invention.
He has 16 years of pharmaceutical industry experience and is currently an Associate Director in Pharmaceutical Development at Allergan Plc (Prior experience at Pfizer Inc and Anadys Pharmaceuticals Inc). Primary areas of research lie in the development, characterization and application of novel drug carrier systems. Supporting drug discovery, early development and repositioning programs and pharmacokinetic, safety and efficacy studies. Hovik is the Adjunct Professor at the University of Southern California and Keck Graduate Institute Schools of Pharmacy, Lecturer at UCSD School of Engineering.